Participated · Series E · Mar 2025

Shoulder Innovations is a medical device company focused on shoulder arthroplasty that designs and commercializes implants and systems for shoulder replacement. Its core product platform centers on the patented InSet™ glenoid design, which testing has shown can significantly reduce glenoid implant micro-motion and simplifies the surgical technique, potentially reducing complications and increasing implant longevity. The company has also developed an anatomic reverse shoulder system designed to work with and maximize the available rotator cuff rather than substitute for it. Shoulder Innovations says it has expanded its product line and strengthened its sales organization and has emerged as a pure‑play leader in shoulder arthroplasty. Financially, the company closed a $40 million Series E equity financing led by U.S. Venture Partners to support commercialization and product development. Proceeds will be used primarily to advance commercialization of the InSet™ Total Shoulder and Reverse Shoulder Arthroplasty Systems, support new product development, and for general corporate purposes. Shoulder Innovations Inc. (SI) is a privately held medical device company based in Grand Rapids, Michigan and described as a leader in the shoulder replacement implant market. The company develops shoulder replacement implants and is supported by a broad team of innovators with experience in the shoulder space. SI announced it has closed an oversubscribed $42 million Series D financing. The financing round was led by Gilde Healthcare Partners. Returning investors included US Venture Partners, Lightstone Ventures and the cultivate (MD) Accelerator Capital fund; new investors include Gilmartin Capital and Aperture Venture Partners. The article does not disclose revenue, user metrics, or detailed use of proceeds. Shoulder Innovations develops a glenoid fixation solution for anatomic shoulder arthroplasty, commercialized as the InSet glenoid. Founded in 2009 and based in Holland, Mich., the company secured issued patents, 510(k) clearance and published multiple peer‑reviewed articles supporting the technology. In 2015 Genesis Innovation Group partnered with the company to provide capital and operational leadership, and Shoulder Innovations recorded its first commercial sale of the InSet glenoid in 2016. Continued investment led by Genesis and its cultivate(MD) Capital Funds and leadership from industry veterans supported ongoing growth and innovation. The company is led by CEO Rob Ball and has completed a $21.6M equity financing to further commercialization. The financing also prompted expansion of the board to six members, including new Series C representatives and two independent directors. Shoulder Innovations is a Holland, Mich.-based medical device company that develops and commercializes shoulder replacement systems. Led by Executive Chairman Rob Ball, the company leverages a patented inset glenoid design to commercialize a shoulder replacement implant system focused on improving outcomes related to glenoid loosening. It designs and commercializes innovative products aimed at improved patient care and reduced overall cost to the healthcare system. The company closed a $2.5M Series A equity funding round and intends to use the funds to accelerate new product development and to acquire inventory and assets to accelerate growth of its current Inset platform technology.

Participated · Series B · Oct 2024

ShiraTronics develops a Migraine Therapy System that delivers neurostimulation intended to reduce headache days and attack severity and improve quality of life for chronic migraine patients. The company reported encouraging reductions in headache days, decreased migraine severity, and improved quality-of-life scores in its first-in-human pilot study. ShiraTronics received Breakthrough Device designation from the FDA's CDRH in 2021. It is now running an FDA-approved pivotal trial (RELIEV-CM2), a multi-center, blinded, randomized, sham-controlled study targeting patients who have failed current medical therapies. The company plans to use new funding to support that pivotal trial, pursue FDA premarket approval, and fund the initial commercial launch of its therapy. Rob Binney serves as CEO and is leading the company through these regulatory and commercialization milestones. ShiraTronics is a Brooklyn Park, Minnesota-based private medical device company focused on an innovative therapy for migraine headaches. The company is developing and clinically testing a neuromodulation technology as its core product. ShiraTronics was spun off from NuXcel, an electrical medical device accelerator. The company is led by President and CEO Lynn Elliott and co-founder and Chairman Mudit K. Jain, PhD. It completed an additional $3M Series A, bringing the Series A to $36M, and intends to use the funds to further accelerate its path to market. ShiraTronics is a Minneapolis-based private medical device company developing an innovative neuromodulation approach to treat migraine headaches. The company is focused on developing and clinically testing its neuromodulation technology. ShiraTronics was seeded in 2019 as a spin-off from NuXcel, a medical device accelerator managed by co-founder Mudit K. Jain, PhD, and Lynn Elliott. Lynn Elliott joined as President and CEO, with Mudit K. Jain serving as co-founder and Chairman of the Board. Prior to the Series A the company was backed by Strategic HealthCare Investment Partners (S.H.I.P.). In October 2019 ShiraTronics completed a $33M Series A financing to advance its clinical development.

Participated · Series B · Aug 2024

XII Medical develops a patient-centric neuromodulation therapy to improve treatment and quality of life for people with obstructive sleep apnea. The company is clinical-stage and its platform is currently limited to investigational use and not available for sale. Led by CEO Garrett Schwab and founded in 2017, XII Medical is based in Union City, California. The company intends to use new funding to further product and clinical development. XII raised $45M in a recently announced financing to support those efforts. XII Medical is a private health technology company focused on treating obstructive sleep apnea (OSA). It is led by President and CEO Garrett Schwab and is based in Union City, California. The company is developing a proprietary, patient-centric solution for people suffering from OSA. XII Medical plans to use new funding to advance the development of that solution. The article does not disclose revenue, users, or other operating metrics. The company previously counted Cleveland Clinic as a founding investor.

Participated · Series B · Apr 2024

Miach Orthopaedics develops the Bridge-Enhanced ACL Restoration (BEAR®) Implant, a bio‑engineered product that facilitates healing of torn anterior cruciate ligaments rather than replacing them. The BEAR Implant acts as a bridge between ACL ends, uses a small amount of the patient’s blood to promote healing, and is resorbed as the ligament repairs. It received De Novo FDA approval in December 2020 and is indicated for skeletally mature patients (14+) with a complete ACL rupture and an ACL stump attached to the tibia. The company reports the BEAR Implant has been used to treat nearly 3,000 patients. Miach says the technology is a paradigm shift from ACL reconstruction because it avoids graft harvest or donor tendons and preserves the ACL’s native attachments. Current priorities include U.S. commercial expansion and clinical initiatives such as the Bridge Registry to gather real‑world outcomes. The company is privately held and located in Westborough, Massachusetts. Miach Orthopaedics is a privately held company in Westborough, Massachusetts, focused on bio-engineered surgical implants for connective tissue restoration, initially commercializing the BEAR Implant for ACL repair. The BEAR Implant is a bridge-enhanced, bio‑engineered device that, when combined with a small amount of the patient’s blood, facilitates healing of a torn ACL and is resorbed as the ligament heals. The device received De Novo FDA approval in December 2020 and is the first medical technology with Level 1 clinical evidence showing it enables the body to heal a torn ACL. Commercial launch began in fall 2021; more than 500 patients have been treated with the BEAR Implant commercially. The company says the BEAR procedure avoids harvesting or using donor tendon grafts and preserves the ACL’s original attachments. The recent financing will fund ongoing operations and expand the U.S. commercial rollout to bring ACL restoration to more patients. MIACH Orthopaedics is focused on the Bridge-Enhanced® ACL Repair (BEAR®), a proprietary bio-engineered sponge used as a bridging scaffold to stimulate healing of torn anterior cruciate ligaments. The BEAR technology has been tested in nearly 100 human patients under an FDA Investigational Device Exemption (IDE). Preclinical studies and the company’s clinical work suggest the BEAR procedure avoids graft harvest and may lower long-term arthritis risk versus conventional ACL reconstruction. MIACH plans to use new funding to accelerate manufacturing capabilities and continue U.S. clinical trials of BEAR. The company has received initial research funding from the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health. MIACH is a privately held company located in Boston, Massachusetts.

Participated · Equity · Apr 2023

Cortica delivers whole-child, value-based autism care through an integrated clinical model that spans medical treatment, neurodiversity-affirming behavioral therapy, developmental therapies (speech, occupational, physical, and music), and family support. The company addresses conditions that frequently co-occur with autism, including sleep disorders, seizures, psychiatric comorbidities, gastrointestinal, communication, behavioral, and sensorimotor issues. Cortica employs more than 1,800 experts across disciplines, including pediatric neurologists, developmental pediatricians, epileptologists, nurse practitioners, speech-language pathologists, occupational and physical therapists, music therapists, BCBA clinicians, and marriage and family therapists. Researchers and physicians in its Cortica innovation network conduct outcomes research, lead clinical trial recruitment, and have assembled a large longitudinal and cross-sectional dataset in autism and neurodevelopment. The company intends to use new funding to continue national scaling of whole-child autism value-based care and to invest in technology, data capture, clinical decision support, research, and optimization of the clinician and patient experience. Cortica is led by CEO and MD Neil Hattangadi and was founded to address the fragmented care journey families experience when seeking autism diagnoses and treatment. Cortica, founded in 2017 and based in San Diego, CA, is a physician-led autism services provider that blends pediatric neurology, developmental pediatrics, research-based therapies, and technology into integrated care programs. The company operates a network of clinicians including pediatric neurologists, developmental pediatricians, nurse practitioners, therapists, and behavior analysts. Cortica has built the Cortica Innovation Network to conduct outcomes research and support clinical trial recruitment. Through organic growth and acquisitions it now owns and operates 23 integrated autism centers and will serve more than 10,000 neurodivergent children and families this year. The organization employs more than 1,600 staff across clinical and support roles. Leadership is headed by CEO Neil Hattangadi. Cortica delivers a “whole-child” medical and behavioral care model for autism and other neurodiverse conditions, integrating medical advances with behavioral analysis, developmental therapies, and family support. Its care platform is enabled by Axon, a technology infrastructure for care coordination and data capture. The company operates centers across five states—California, Illinois, New Jersey, New York and Texas—each led by neurologists and other physicians. Cortica is running multiple clinical trials, including several funded by the National Institutes of Health, across neuroimaging, neuromodulation, molecular diagnostics, biotech therapeutics, and digital therapeutics. The company plans to use new investment to bring its care model to more families across the country. Leadership is headed by co-founder and CEO Neil Hattangadi, M.D. Cortica is a tech-enabled clinical services provider delivering coordinated care for autism and other neurodevelopmental conditions. Its treatment model assembles multidisciplinary teams to foster holistic child development and empower families. The model combines an “inside out” focus on medical diagnosis, nutrition, supplements, neurofeedback and other health interventions with an “outside-in” focus on environmental and learning optimizations such as speech and language therapy, neurological music therapy, occupational therapy, progressive ABA, and parent education. Cortica conducts sponsored and NIH-funded research and is considered a leader in autism outcomes research, having run multiple clinical studies demonstrating therapeutic benefits and cost-effectiveness of its platform. The company is accelerating growth by expanding centers across multiple states. Cortica is led by co-founders Neil Hattangadi, M.D. (CEO) and Suzanne Goh, M.D., BCBA (Chief Medical Officer), who met at Harvard Medical School.